



# Resource impact statement

Resource impact

Published: 15 December 2022

[www.nice.org.uk](http://www.nice.org.uk)

## No significant resource impact is anticipated

NICE has recommended avatrombopag within its marketing authorisation, as an option for treating primary chronic immune thrombocytopenia (ITP) refractory to other treatments (for example, corticosteroids, immunoglobulins) in adults. It is only recommended if the company provides it according to the commercial arrangement.

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).

This is because avatrombopag is a further treatment option for patients alongside other thrombopoietin receptor agonists and the overall cost of treatment for this patient group will be similar.

The company has a commercial arrangement (simple discount patient access scheme). This makes avatrombopag available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.

ISBN: 978-1-4731-4904-5